Zusammenfassung
Aufgrund der Häufigkeit okkulter pulmonaler Metastasen bereits bei Diagnosestellung eines Osteosarkoms ist die Chemotherapie ein elementarer Bestandteil der multimodalen Therapie dieser Erkrankung. Seit Etablierung der adjuvanten Chemotherapie in den 80er Jahren wurden bedeutende Fortschritte durch konsekutiv durchgeführte multizentrische Studien erreicht. Weitere Verbesserungen sind nur durch große internationale Studien zu erreichen. Hierbei stellt die aktuelle EURAMOS-1 – Studie, die durch Zusammenschluss mehrerer großer Studiengruppen in Europa und USA zustande kam, einen wesentlichen Schritt dar. Ein weiterer Meilenstein ist die EURO-B.O.S.S.-Studie, die erstmals systematisch die Therapie von älteren Patienten mit Osteosarkomen und anderen hochmalignen Knochentumoren untersucht.
Abstract
Due to the frequency of occult pulmonary metastases at the time of first diagnosis of osteosarcoma, chemotherapy plays a major role in the interdisciplinary treatment of this disease. Since the establishment of adjuvant chemotherapy in the 1980s important improvements have been made through consecutive multicentre clinical trials. Further progress can only be achieved with large, international, randomized clinical trials such as EURAMOS 1, an intergroup trial with participation of the major osteosarcoma study groups in Europe and the US. Another important step is the EURO-B.O.S.S. trial; the first study on osteosarcoma and other high-grade bone tumors in patients over the age of 40 years.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Bacci G, Ferrari S, Donati D et al. (1998) Neoadjuvant chemotherapy for osteosarcoma of the extremity in patients in the fourth and fifth decade of life. Oncol Rep 5:1259–1263
Bacci G, Briccoli A, Longhi A et al. (2005) Treatment and outcome of recurrent osteosarcoma: Experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol 44:748–755
Bielack SS, Kempf-Bielack B, Delling G et al. (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776–790
Davis AM, Bell RS, Goodwin PJ (1994) Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 12:423–431
Eilber F, Giuliano A, Eckardt J et al. (1987) Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 5:21–26
Enneking WF, Spanier SS, Goodman MA (1980) A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 153:106–120
Goi K, Sugita K, Tezuka T et al. (2005) A successful case of allogeneic bone marrow transplantation for osteosarcoma with multiple metastases of lung and bone. Bone Marrow Transpl Oct 31:1–2 (epub)
Grimer RJ, Cannon SR, Taminiau AM et al. (2003) Osteosarcoma over the age of fourty. Eur J Cancer 39:157–163
Huvos AG (1986) Osteogenic sarcoma of bones and soft tissues in older persons. A clinicopathologic analysis of 117 patients older than 60 years. Cancer 57:1442–1449
Laverdiere C, Kolb EA, Supko JG et al. (2003) Phase II Study of Ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 98:832–840
Link MP, Goorin AM, Miser AW et al. (1986) The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314:1600–1606
Mansky PJ, Liewehr DJ, Steinberg SM et al. (2002) Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: Significant reduction of insulin-like growth factor-1 serum levels. J Pediatr Hematol/Oncol 24:440–446
Meyers PA, Schwartz CL, Krailo M et al. (2005) Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin and high-dose methotrexate. J Clin Oncol 23:2004–2011
Mintz MB, Sowers R, Brown KM et al. (2005) An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res 65:1748–1754
Müller CR, Smeland S, Bauer HCF et al. (2005) Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: long term results of Karolinska Hospital series. Acta Oncol: 44:475–480
Naka T, Fukuda T, Shinohara N et al. (1995) Osteosarcoma versus malignant fibrous histiocytoma of bone in patients older than 40 years. A clinicopathologic and immunohistochemical analysis with special reference to malignant fibrous histiocytoma-like osteosarcoma. Cancer 76:972–984
Nathrath M, Kremer M, Letzel H et al. (2002) Expression von Genen mit möglicher prognostischer Bedeutung für das Ansprechen auf Chemotherapie bei Patienten mit Osteosarkom. Klin Pädiatr 214:230–235
Patel SR, Papadopolous N, Raymond AK et al. (2004) A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis. Cancer 101:156–163
Rosen G, Caparros B, Huvos AG et al. (1982) Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49:1221–1230
Salzer-Kuntschik M, Brand G, Delling G (1983) Determination of the degree of morphological regression following chemotherapy in malignant bone tumors. Pathologe 4:135–141
Interessenkonflikt:
Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schoeler, D., Reichardt, P. Aktuelle Entwicklungen in der Chemotherapie des Osteosarkoms. Onkologe 12, 128–136 (2006). https://doi.org/10.1007/s00761-005-1013-3
Issue Date:
DOI: https://doi.org/10.1007/s00761-005-1013-3